Get started
Author

Gabriela Gomez Rendon

Observed names: G. Gomez Rendon, Gabriela Gomez-Rendon, Gabriela Gomez‐Rendon
ORCID: 0009-0007-1303-5201
Observed ORCID: 0009-0007-1303-5201
OpenAlex ID: A5093533632
Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
2018 · Linda Nasser, Malgorzata Rozycka, et al. · Clinical ophthalmology · 29
PDF
Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension
2025 · Bettia Celestin, Shadi P. Bagherzadeh, et al. · CHEST Journal · 16
Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis
2024 · Oksana A. Shlobin, Gary Bruce, et al. · Pulmonary Circulation · 6
PDF
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
2024 · Robert P. Frantz, Shashank S. Desai, et al. · Pulmonary Circulation · 6
PDF
The Role of Telehealth in PAH Management: Benefits, Barriers, and Solutions
2025 · Susanne McDevitt, Martha Kingman, et al. · Pulmonary Circulation · 4
PDF
Patient Perspectives on Fixed Dose Combination Therapy for Pulmonary Arterial Hypertension: Exploratory Focus Group Research
2025 · Jean M. Elwing, Stacey Barta, et al. · Pulmonary Circulation · 3
PDF
Treatment Patterns in Patients With Incident Pulmonary Hypertension
2025 · Sarah L. Khan, Carly J. Paoli, et al. · CHEST Journal · 2
A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension
2025 · Rajan Saggar, Nora Rahhali, et al. · Pulmonary Circulation · 2
Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension: Results of a Systematic Literature Review
2024 · R. Saggar, N. Rahhali, et al. · 2
Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)
2025 · Nicholas A. Kolaitis, Martha Kingman, et al. · Pulmonary Circulation · 1
PDF
Abstract 13633: Modern Treatment Patterns in Incident Pulmonary Arterial Hypertension (PAH) Patients: Real-World Data From the Pulmonary Hypertension Association (PHA) Registry
2023 · Carly J Paoli, Noah Kime, et al. · Circulation · 1
Real-World Treatment Patterns and Burden of Chronic Thromboembolic Pulmonary Hypertension Patients across Consultation Settings in the USA
2025 · Belinda Rivera-Lebron, Alison Witkin, et al. · Pulmonary Therapy
PDF
Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i)
2025 · Nicholas A. Kolaitis, Martha Kingman, et al. · JHLT Open
PDF
Provider Preferences Regarding the Use of Combination ERA+PDE5i for the Treatment of Pulmonary Arterial Hypertension: Results From a Discrete Choice Experiment
2024 · N.A. Kolaitis, M. Kingman, et al.
Echocardiography in Pulmonary Arterial Hypertension Using Deep Learning Segmentation Algorithms
2024 · B.E. Celestin, S.P. Bagherzadeh, et al. · The Journal of Heart and Lung Transplantation
PDF
Fully Automated versus Core Laboratory Analysis of Tricuspid Regurgitation Maximal Velocity in Patients with Pulmonary Hypertension
2024 · B. Celestin, S. Bagherzadeh, et al. · The Journal of Heart and Lung Transplantation
PDF
Practices Affecting Opsumit ® and Uptravi ® Patient Persistence Rates Utilizing Pulmonary Arterial Hypertension Clinical Site and Patient Perspectives: A US Qualitative Research Analysis (PERSIST)
2023 · C. Mcevoy, F. Rogers, et al.
Works count: 17
Citation count: 72
H-index: 4
I10-index: 2
Year
Topic
Type